COLLEGIUM PHARMACEUTICAL, INC

Collegium Pharmaceutical completed the acquisition of Azstarys on May 12, 2026, expanding its commercial presence into the ADHD market. The acquisition involved approximately $655.6 million in cash consideration, funded by existing cash and a $300 million term loan. For the second quarter of 2026, the company reported a net loss of $(15.05) million, a decrease from a net income of $11.98 million in the prior year, despite product revenues increasing to $199.88 million from $188 million. The financial results reflect significant acquisition-related expenses totaling $23.3 million for the quarter.

Collegium Pharmaceutical reported Q2 2026 net revenues of $199.9 million, a 6% increase year-over-year, driven by strong demand in its ADHD portfolio, including JORNAY PM and the newly acquired AZSTARYS. The company completed the acquisition of AZSTARYS in May, which contributed $12.9 million in partial-quarter net revenue. However, the company updated its full-year 2026 financial guidance, lowering projections for Product Revenues, Net, and Adjusted EBITDA, primarily due to lower-than-expected revenue from the Nucynta authorized generic versions.

Collegium Pharmaceutical, Inc. announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston during the first quarter of 2027. This strategic move reflects the company's continued evolution as a diversified biopharmaceutical firm, aiming to position it within Boston's leading healthcare and life sciences ecosystem. The new headquarters will support future growth and reinforce Collegium's long-standing commitment to Massachusetts, where the company was founded.

Collegium Pharmaceutical, Inc. announced it granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026. These inducement grants were made under the Company's 2026 Inducement Plan, adopted by the board on May 11, 2026, to attract new talent. The RSUs will vest in installments over three years, with one-third vesting on June 10, 2027, and the remainder annually thereafter, contingent on continued employment.

Collegium Pharmaceutical, Inc. announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event is scheduled for Wednesday, June 3, 2026, at 1:20 p.m. ET in New York, NY. A live webcast will be available on the company's investor relations website, with a replay archived for 90 days following the presentation.

Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD medicine, from Corium Therapeutics for approximately $650 million. This strategic move strengthens Collegium's ADHD portfolio and is expected to be immediately accretive, leading to raised 2026 financial guidance. The company now projects total product revenues of $865 to $895 million and adjusted EBITDA of $475 to $500 million. Additionally, Chief Commercial Officer Scott Dreyer and Chief Medical Officer Thomas Smith will depart.

Collegium Pharmaceutical announced an agreement to acquire AZSTARYS, an ADHD treatment, for $650 million in cash plus up to $135 million in milestone payments, expected to close in Q2 2026. Concurrently, the company reported strong first-quarter 2026 financial results, with net income surging 499% to $14.5 million and diluted earnings per share increasing to $0.40. Net product revenues grew 8.9% year-over-year to $193.5 million.

Collegium Pharmaceutical reported strong financial results for the first quarter ended March 31, 2026, with total net revenues increasing 9% year-over-year to $193.5 million. The company's JORNAY PM product saw significant growth, with net revenue up 36% to $38.9 million, and the pain portfolio also delivered solid performance with a 4% increase to $154.6 million. Collegium reaffirmed its full-year 2026 guidance for its current business and remains on track to close the acquisition of AZSTARYS in the second quarter of 2026, which is expected to strengthen its ADHD portfolio and be immediately accretive.

Collegium Pharmaceutical, Inc. announced it will release its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Following the release, the company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can access the call via dial-in numbers or an audio webcast on the company's website, with a replay available afterward.

Collegium Pharmaceutical, Inc. announced a planned board refreshment, nominating Michael Donovan for election at its 2026 Annual Meeting of Shareholders. Mr. Donovan, a Certified Public Accountant with over 36 years of experience, brings extensive financial and life sciences expertise from his tenure as an audit Partner at Ernst & Young LLP. Concurrently, Dr. John Fallon, who has served on the Board since 2016, will retire and not stand for re-election, a decision stated to be part of the Board's ongoing succession planning rather than any disagreement. These changes aim to enhance the Board's financial acumen and strategic oversight.